Quick Answer
MIRA PHARMACEUTICALS, INC. reported R&D Expense of $1.72 million for fiscal year 2025.
MIRA PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.72M | -48.0% |
| 2024 | $3.31M | +110.1% |
| 2023 | $1.57M | -33.1% |
| 2022 | $2.35M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $412.6K | -61.3% | -16.8% |
| June 30, 2025 | $496.2K | -19.2% | +57.8% |
| March 31, 2025 | $314.4K | -58.8% | -70.5% |
| September 30, 2024 | $1.07M | +5.1% | +73.7% |
| June 30, 2024 | $614.5K | +708.3% | -19.4% |
| March 31, 2024 | $762.3K | +180.7% | -24.9% |
| September 30, 2023 | $1.02M | +42.0% | +1105.0% |
| June 30, 2023 | -$101.0K | — | -137.2% |
- MIRA PHARMACEUTICALS, INC. showed a decrease of -48.0% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, MIRA PHARMACEUTICALS, INC.’s r&d expense has declined by 26.9% (from $2.35 million to $1.72 million).
- The most recent figure is from MIRA PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: